Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

870 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Martin AG, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. Concin N, et al. Among authors: vergote i. Radiother Oncol. 2021 Jan;154:327-353. doi: 10.1016/j.radonc.2020.11.018. Radiother Oncol. 2021. PMID: 33712263
Endometrial cancer.
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Amant F, et al. Among authors: vergote i. Lancet. 2005 Aug 6-12;366(9484):491-505. doi: 10.1016/S0140-6736(05)67063-8. Lancet. 2005. PMID: 16084259 Free article. Review.
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Colombo N, et al. Among authors: vergote i. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2. Crit Rev Oncol Hematol. 2006. PMID: 17018256 Review.
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups. Vergote I, et al. Int J Gynecol Cancer. 2010 Apr;20(3):476-8. doi: 10.1111/IGC.0b013e3181d3caa8. Int J Gynecol Cancer. 2010. PMID: 20375816 No abstract available.
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Harter P, et al. Among authors: vergote i. Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd. Int J Gynecol Cancer. 2011. PMID: 21270612
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Hofstetter G, et al. Among authors: vergote i. Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18. Br J Cancer. 2011. PMID: 22009029 Free PMC article.
870 results